1 The ratio of BRAFV600E alleles can be used to assess the biological

2 behavior of papillary thyroid carcinoma

- 3 Dingcun Luo^{1*,#}, Yeqin Ni^{2*}, Shirong Zhang^{3,#}, Yanping Xun³, Pan Zhao⁴, Fan
- 4 Wu², Tianhan Zhou², Jingjing Shi¹, Si Lu⁵, Sihan Sun⁶, Kaining Lu⁶
- ⁵ ¹Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital,
- 6 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China
- ⁷ ²Zhejiang Chinese Medical University, The Fourth Clinical College, Hangzhou
- 8 310006, Zhejiang, China
- ⁹ ³Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital,
- 10 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China
- ⁴Department of Pathology, Affiliated Hangzhou First People's Hospital,
- 12 Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China
- ¹³ ⁵Institute of Translational Medicine, Zhejiang University School of Medicine,
- 14 Hangzhou 310058, Zhejiang, China
- ¹⁵ ⁶Nanjing Medical University, Nanjing 211166, Jiangsu, China
- ¹⁶ *These authors contributed equally to this work
- 17
- ¹⁸ [#]Corresponding authors
- 19 Dingcun Luo, B.M

- 20 Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital,
- 21 Zhejiang University School of Medicine
- No. 261, Huansha Road, Shangcheng district, Hangzhou 310006
- P. R. China
- 24 E-mail: <u>ldc65@163.com</u>
- 25 Shirong Zhang, M.D, Ph.D
- 26 Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital,
- 27 Zhejiang University School of Medicine
- No. 261, Huansha Road, Shangcheng district, Hangzhou 310006
- 29 P. R. China
- 30 E-mail: shirleyz4444@163.com
- 31

33 ABSTRACT

34 **Background** The BRAFV600E mutations is an important molecular event in the occurrence and development of papillary thyroid carcinoma (PTC). A 35 qualitative detection of the BRAFV600E mutation is still insufficient to explain 36 the biological behavior of PTC. Though quantitative detection of the 37 38 BRAFV600E mutation can reflect certain characteristics of PTC, its clinical 39 value is still controversial. We aimed to investigate the association between the ratio of BRAFV600E alleles and clinicopathological parameters in PTC 40 41 patients.

Methods Genomic DNA was extracted from specimens obtained from 329 PTC patients undergoing thyroidectomy. The ratio of BRAFV600E alleles was determined by amplification refractory mutation system (ARMS) and droplet digital polymerase chain reaction (ddPCR). Inconsistent results were further verified by next-generation sequencing (NGS). The clinicopathologic features, clinical tumor stage, and tumor recurrence risk stratification of all patients were correlated with the ratio of BRAFV600E alleles.

Results The sensitivity of ddPCR was superior to that of ARMS and almost the same as that of NGS. In total, 275 of 329 patients had the BRAFV600E mutation as determined by ARMS, ddPCR and NGS. The ratio of BRAFV600E alleles ranged from 0.17%-48.0%, with a median ratio of 12.58%, and

53	significantly correlated with tumor size (p<0.001), capsule or extrathyroidal
54	invasion (p<0.001), the number or rate of lymph node metastases (p<0.001),
55	tumor stage (p=0.006) and tumor recurrence risk (p<0.001) but not with sex,
56	age or multifocality. The ratio of BRAFV600E alleles was much lower in PTC
57	patients with Hashimoto's thyroiditis than in those without (p<0.001).
58	Conclusions The ratio of BRAFV600E alleles can reliably reflect the biological
59	behavior of PTC, making it a molecular-based stratification index of recurrence
60	risk. The quantitative detection of BRAFV600E has the potential to guide the
61	clinical diagnosis and treatment of PTC.
62	Keywords: papillary thyroid carcinoma, BRAF, droplet digital PCR,
63	quantification, biological behavior
64	

65 **INTRODUCTION**

Papillary thyroid carcinoma (PTC) is the most common malignant tumor in the endocrine system, and its incidence has rapidly increased in the past decade(1). Although most PTCs progress slowly, with a high survival rate and a low recurrence rate, some patients are very prone to cervical lymph node metastasis (LNM) and distant metastasis and even die of persistent or recurrent disease that is refractory to conventional therapies(2-4). Large-scale multicenter studies have demonstrated an association between BRAFV600E

73 and PTC prognosis as well as PTC-specific mortality(5). Data from 74 meta-analyses have consistently indicated that the presence of the 75 BRAFV600E mutation in PTC is associated with extrathyroidal invasion, lymph 76 node metastasis, advanced TNM stage, and tumor recurrence(6-9). Interestingly, PTCs with aggressive biological behaviors, such as those with 77 78 the BRAFV600E mutation, can occur in small tumors, and thyroid microcarcinomas with the BRAFV600E mutation are frequently associated with 79 80 extrathyroidal extension and lymph node metastasis(10).

BRAF is a cytoplasmic serine-threonine protein kinase. Among the three forms of RAF kinases, BRAF is the most potent activator of the mitogen activated protein kinase (MAPK) pathway. The vast majority of BRAF allele alterations are characterized by a single amino acid substitution of valine by glutamic acid in a mutational hotspot at amino acid position 600 (BRAF c.1799T>A (p.Val600Glu), referred to hereafter as BRAFV600E(11-13). The BRAFV600E mutation is a negative prognostic marker in PTC.

With detection 88 the development of techniques including system (ARMS) and 89 amplification refractory mutation next-generation sequencing (NGS), the BRAFV600E mutation can be found in approximately 90 79%-87% of PTC patients, and it is an important molecular marker for PTC 91 92 diagnosis, treatment and prognosis(12-18). The significance of the

93	BRAFV600E mutation in the qualitative diagnosis of thyroid nodules is
94	increasing, but the association between the BRAFV600E mutation and
95	clinicopathological features and its impact on clinical outcomes remain
96	challenging or unclear in PTC, especially in patients with microcarcinoma(19,
97	20). Guerra et al. demonstrated that completely clonal PTC harboring the
98	BRAFV600E mutation was rare and that PTC was frequently associated with a
99	mixture of wild-type and mutant BRAF alleles. The association between the
100	BRAFV600E mutation and the clinicopathological features of PTC should be
101	reevaluated, taking into account the fraction of mutant BRAF alleles(21, 22).
102	We speculated that the larger the proportion of mutated BRAF alleles detected,
103	the more aggressive the tumor. Therefore, the quantitative detection of
104	BRAFV600E alleles should help clarify the relationship between the
105	BRAFV600E mutation and the clinical behavior of PTC patients.

106 Droplet digital PCR (ddPCR) is a novel technology that provides sensitive and absolute nucleic acid quantification. It is far more sensitive and specific 107 108 than other methods because of amplification at the nanoliter level and can accurately measure trace amounts of nucleic acids. Detection of the 109 110 BRAFV600E mutation by ddPCR has been demonstrated in melanoma 111 samples and pancreas fine needle aspiration (FNA) specimens(23-25). A recent study showed that mutant BRAFV600E was detected in 56%(42/75) of 112 113 PTC tumors by ddPCR and that the ratio of mutant/total BRAF alleles varied 6

114	from 4.7% to 47.5%, suggesting that ddPCR detection of the BRAFV600E
115	mutation should be a suitable assay for the molecular-based stratification of
116	prognosis in patients with PTC(26).
117	According to the 2015 American Thyroid Association (ATA) Management
118	Guidelines for Differentiated Thyroid Cancer on the risk stratification of PTC
119	recurrence(27), in this study, we investigated a correlation between the ratio of
120	BRAFV600E alleles and disease risk (high, intermediate and low). We aimed
121	to provide a reliable and molecular-based risk stratification for PTC patients.
122	To this end, we used ddPCR and ARMS to detect the ratio of BRAFV600E
123	alleles in PTC tissues and paracancerous tissues. If the results of ddPCR and
124	ARMS were inconsistent, NGS was used for further clarification.

125

126 MATERIALS AND METHODS

127 Patients and sample correction

A total of 329 PTC patients who visited Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine between 2016 and 2018, and their matched formalin-fixed paraffin-embedded (FFPE) blocks were randomly and consecutively selected and analyzed for the BRAFV600E mutation. The exclusion criteria were as follows: (1) patients who had a history of treatments for thyroid cancer, (2) patients with other cervical malignant tumors, and (3)

134 patients with both thyroid cancer and Graves' disease or other endocrine 135 disorder. Fresh tumor tissues and their paracancerous tissues were carefully 136 dissected during the operation in 10 of 329 PTC patients. PTC tissues were 137 collected from the center of the tumor lesions, and paracancerous tissues were obtained at least 2 cm from the margins of the tumor lesions. Histological 138 139 diagnoses were established according to the WHO classification after the examination of hematoxylin and eosin-stained slides. The pathological 140 141 diagnosis was performed by two thyroid pathologists. If there were different 142 opinions, a third expert participated in the diagnosis, and the opinions of the 143 two experts were used as the final diagnosis. A total of 144 PTC patients 144 underwent total thyroidectomy, and 185 underwent hemithyroidectomy. All 145 patients underwent neck central compartment lymph node dissection. 146 Fifty-seven patients underwent therapeutic neck lateral compartment lymph 147 node dissection. In this study, we extracted the following clinicopathologic 148 variables: sex, age, multifocality, tumor diameter, capsule invasion, 149 extrathyroid extension, Hashimoto's thyroiditis (HT) and lymph node 150 metastasis. Each patient was classified according to the 8th revision of the 151 TNM staging system by the American Joint Committee on Cancer(AJCC)(28). 152 The diagnostic criteria of Hashimoto's thyroiditis were based on pathology or 153 serum thyroid globulin antibody and peroxidase antibody combined with 154 ultrasound characteristics(29,30). According to the risk of structural disease

155 recurrence offered by the 2015 ATA Management Guidelines for Differentiated 156 Thyroid Cancer, all patients were stratified as low, intermediate and high 157 risk(27). All patients were followed up for a period of 16-50 months. One 158 patient died of lung metastasis, and another patient developed recurrent cervical lymph node metastases. The remaining patients survived without 159 recurrence. This study was approved by the Institutional Ethics Committee of 160 Affiliated Hangzhou First People's Hospital, Zhejiang University School of 161 162 Medicine. All patients provided informed consent, and they all agreed to 163 participate in this study. All procedures were performed in accordance with the Declaration of Helsinki. 164

165 **DNA extraction**

The extraction of DNA from fresh frozen thyroid tissue was performed 166 167 using a QIAamp DNA Mini Kit (QIAGEN Inc., Hilden), following the 168 manufacturer's instructions. The FFPE blocks of PTC samples were deparaffinized with xylene and rehydrated through ethanol (100%). Then, the 169 extraction of DNA was performed using a QIAamp DNA FFPE Tissue Kit 170 171 (QIAGEN Inc., Hilden) according to the manufacturer's instructions. DNA 172 quantification was performed on a NanoDrop 1000 (Thermo Fisher Inc., 173 Waltham) according to the manufacturer's instructions. The DNA had a purity 174 $1.8 \leq A_{260}/A_{280} \leq 2.0$ and a concentration greater than 10.0 mg/L.

175 **ddPCR**

ddPCR was performed on a QX-200 Droplet Digital PCR System (Bio-Rad 176 Inc., Hercules). The primer and probe for detection of the BRAFV600E 177 mutation were purchased from Bio-Rad. Two probes with one nucleotide 178 179 difference that target the mutated region were labeled with carboxyfluorescein 180 (FAM) and green fluorescent protein (VIC) dyes to detect mutant and wild-type BRAFV600E alleles, respectively. The final TagMan PCR mixture (20 µL) 181 182 containing 50 ng of template DNA was prepared. The thermal cycling conditions for the BRAFV600E detection assay comprised a 10-min incubation 183 184 at 95 °C followed by 40 cycles at 94 °C for 15 s and 58 °C for 1 min, followed 185 by a hold step at 4 °C for 5min. The analyses of ddPCR data for allele calling was performed with Quanta Soft software version 1.3.2.0 (Bio-Rad). All 186 187 experiments and data analysis were performed according to the 188 manufacturer's instructions (YuanQi BioTech, China). Considering that single, 189 nonspecific droplets were occasionally found in the positive area, the presence 190 of at least three droplets with the FAM signal was defined as positive signal for the mutation. The ratio of BRAFV600E mutations was calculated with the 191 192 following equation: (FAM positive droplet + FAM/VIC dual positive 193 droplet)/(FAM positive droplet + VIC positive droplet + FAM/VIC dual positive 194 droplet). The threshold was set at 0.1% of the ratio, as described in the 195 manufacturer's instructions.

196 **ARMS**

197	ARMS was performed using an ABI 7500 system (Thermo Fisher Inc.,
198	Waltham). The ARMS kit for BRAFV600E mutation detection was purchased
199	from AccBio Inc. (Beijing). The final PCR mixture (45 $\mu L)$ was amplified under
200	the following conditions: 1 cycle at 95 °C for 5 min; 15 cycles at 95 °C for 25 s
201	and 64 $^{\circ}\text{C}$ for 20 s, followed by 72 $^{\circ}\text{C}$ for 20 s; and 31 cycles at 93 $^{\circ}\text{C}$ for 25 s,
202	60 °C for 35 s and 72 °C for 20 s. The FAM signals were detected at 60 °C. The
203	definition of BRAFV600E status was classified by the FAM cycle threshold(Ct)
204	value: (1) if the Ct value was <35, the sample was defined as positive; (2) if the
205	Ct value was between 35-38, the sample was defined as suspicious; and (3) if
206	the Ct value was >38, the sample was defined as negative.

207 NGS

208 Due to the inconsistent results produced by ddPCR and ARMS, 16 of 329 specimens were analyzed with an AmpliSeq Cancer Hotspot Panel (v2) (Life 209 210 Technologies Inc., Carlsbad) as described previously(31). BRAFV600E 211 sequencing data were analyzed using Torrent Suite (Life Technologies Inc., 212 Carlsbad). Mutations were identified and annotated through both Torrent 213 Variant Caller and a direct visual inspection of the binary sequence 214 alignment/map (BAM) file on the Broad Institute's Integrative Genomics Viewer 215 (IGV) (32).

216 Normalization of BRAFV600E alleles to the proportion of neoplastic cells

217	The ratio of BRAFV600E alleles obtained by ddPCR was normalized to the
218	proportion of neoplastic cells (vs contaminant cells, such as inflammatory or
219	stromal cells) in each sample using the following formula: (normalized ratio of
220	BRAFV600E alleles = ratio of BRAFV600E alleles / proportion of neoplastic
221	cells). The proportion of neoplastic cells was calculated as a percentage after a
222	careful microscopic evaluation of the tumor area on the hematoxylin and
223	eosin-stained slide by two pathologists separately.

224 Statistical Analysis

225 Medians with interquartile ranges were calculated for continuous variables, 226 and numbers and percentages were calculated for categorical variables. 227 Normality was tested with Kolmogorov-Smirnov tests. The Mann-Whitney U 228 test was used to compare continuous, nonnormally distributed variables. The 229 Kruskal-Wallis H test was used to compare variables between more than two 230 groups. Pearson's chi-square test or Fisher's exact test was used to compare 231 categorical variables. The Spearman rank-correlation test was used to analyze 232 the correlation between two continuous variables. All statistical analyses were 233 performed with SPSS statistical software (version 25.0). A P value<0.05 was 234 considered statistically significant.

235

236 **Results**

237 Detection of the BRAFV600E mutation by ddPCR, ARMS and NGS

238 Among the 329 patients, 274 (83.28%) were detected the BRAFV600E 239 mutation by ddPCR, and 263 (79.94%) were found to have the BRAFV600E mutation by ARMS. There was no significant difference between the data 240 241 obtained from the two methods (p=0.268, Table 1). The ARMS and ddPCR 242 results were inconsistent for 16 patients; therefore, NGS was conducted. The 243 results obtained from NGS were consistent with those obtained from ddPCR for 244 15 patients and with those obtained from ARMS for one patient (Supplemental 245 table 1). Consistent results between the two methods were considered the final 246 result, revealing that 275 of 329 patients had the BRAFV600E mutation 247 (83.58%).

248 In 274 of 275 patients with the BRAFV600E mutation as determined by 249 ddPCR, the ratio of BRAFV600E alleles varied from 0.17% to 48.0% (mean 250 15.79%), the quartiles were 6.3% and 22.71% (median 12.58%). If the ratios of BRAFV600E alleles obtained by ddPCR were divided into three groups, >10%, 251 252 1-10%, and <1%, the positive rates of BRAFV600E mutations detected by 253 ARMS were 98.1%, 94.1%, and 69.2%, respectively (Figure 1). Although there 254 was no statistically significant difference in the sensitivity of ddPCR versus that 255 of ARMS, the sensitivity of BRAFV600E mutation detection by ddPCR was

256	notably higher than that of ARMS. Additionally, analysis by ddPCR indicated
257	that there was a difference in the average ratio of BRAFV600E alleles between
258	10 fresh frozen tissues and 10 FFPE-matched specimens (30.40% vs. 23.00%).
259	However, paraffin tissues were utilized uniformly for analysis in the present
260	study because of the statistically nonsignificant difference (P=0.302). No
261	BRAFV600E mutation was found in 10 thyroid paracancerous tissue
262	specimens.
263	Detection of the BRAFV600E mutation in PTC by ddPCR
264	Relationship between the ratio of BRAFV600E alleles and
265	clinicopathological features of PTC
266	First, we analyzed the relationship between the BRAFV600E mutation
266 267	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we
266 267 268	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and
266 267 268 269	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological
266 267 268 269 270	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological features of PTC patients were not closely related to the BRAFV600E mutation
 266 267 268 269 270 271 	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological features of PTC patients were not closely related to the BRAFV600E mutation status (Table 2) but were closely correlated to the ratio of BRAFV600E alleles
266 267 268 269 270 271 272	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological features of PTC patients were not closely related to the BRAFV600E mutation status (Table 2) but were closely correlated to the ratio of BRAFV600E alleles (Table 3). The ratio of BRAFV600E alleles was significantly associated with
266 267 268 269 270 271 272 273	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological features of PTC patients were not closely related to the BRAFV600E mutation status (Table 2) but were closely correlated to the ratio of BRAFV600E alleles (Table 3). The ratio of BRAFV600E alleles was significantly associated with tumor size, capsule invasion/extrathyroidal extension, LNM, TNM stage, HT,
266 267 268 269 270 271 272 273 274	First, we analyzed the relationship between the BRAFV600E mutation status and clinicopathological features of PTC patients (Table 2). Second, we determined the relationship between the ratio of BRAFV600E alleles and clinicopathological features (Table 3). We found that the clinicopathological features of PTC patients were not closely related to the BRAFV600E mutation status (Table 2) but were closely correlated to the ratio of BRAFV600E alleles (Table 3). The ratio of BRAFV600E alleles was significantly associated with tumor size, capsule invasion/extrathyroidal extension, LNM, TNM stage, HT, and ATA recurrence risk. Sex, age and multifocality were independent of the

276 Relationship between the ratio of BRAFV600E alleles and maximal tumor

277 diameter

278	In our cohort, the maximal tumor diameter ranged from 2 mm to 55 mm,
279	with a median diameter of 8 mm. Patient samples were classified into three
280	groups according to the maximal tumor diameter, \leq 10 mm, 11-20 mm, and >20
281	mm, and their median ratios of BRAFV600E alleles were 8.13%, 20.29% and
282	32.67%, respectively. The ratio of BRAFV600E alleles was significantly
283	different between these three groups (p<0.001) (Table 3). It appeared that
284	there was a positive correlation between the ratio of BRAFV600E alleles and
285	maximal tumor diameter (Figure 2). Thus, the ratio of BRAFV600E alleles
286	increased with increasing maximal tumor diameter (Spearman's rho=0.413,
287	p<0.0001; R ² =0.189, p<0.0001).

Relationship between the BRAFV600E allele ratio and capsule/extrathyroidal invasion

The median ratios of BRAFV600E alleles in 329 patients with and without thyroid capsule/extrathyroidal invasion were 15.20% and 7.64%, respectively. The ratios of BRAFV600E alleles were significantly different between these two groups of patients (p<0.001, Figure 3).

Relationship between the BRAFV600E allele ratio and lymph node
 metastasis

296	A total of 154 patients had LNM, and 175 did not involve metastasis in our
297	study. Among the patients with LNM, 71 were defined as having low-volume
298	lymph node metastasis, with \leq 5 pathologic metastatic lymph nodes and foci <2
299	mm in the largest dimension, and 81 were defined as having high-volume
300	lymph node metastasis, with >5 pathologic metastatic lymph nodes or foci \geq 2
301	mm in the largest dimension. The median ratios of BRAFV600E alleles were
302	8.00% , 10.33% and 17.17%, respectively, in patients with no, low-volume and
303	high-volume lymph node metastasis. The difference between these three
304	groups was significant (p<0.001, Table 3). The ratio of BRAFV600E alleles was
305	positively correlated with the number of metastatic lymph nodes (Spearman's
306	rho=0.220, p<0.0001; R^2 =0.070, p<0.0001, Figure 4) and the rate of lymph
307	node metastasis (metastatic/dissected lymph nodes) (Spearman's rho=0.232,
308	p<0.0001; R ² =0.058 , p<0.0001, Figures 5).

Relationship between the BRAFV600E allele ratio and Hashimoto's thyroiditis

Eighty-seven PTC cases had accompanying HT. The median ratios of BRAFV600E alleles in PTC patients with and without HT were 5.38% and 12.64%, respectively, with a significant difference(p<0.001, Table 3, Figure 6). HT was most frequently observed in patients with stage I PTC than those with other stages of PTC. It was also noted that stage I PTC was associated with a

316 low BRAFV600E mutation ratio (Table 4), suggesting that HT may has a

negative impact on the BRAFV600E mutation in PTC.

318 Relationship between the BRAFV600E allele ratio and tumor stage

According to the 8th revision of the TNM staging system by the AJCC, there were 282 patients with stage I disease, 40 patients with stage II disease, and 7 patients with stage III or IV disease among all 329 patients, and their median ratios of the BRAFV600E alleles were 8.90%, 14.20% and 29.00%, respectively, with significant differences(p=0.006). We found that the BRAFV600E mutation ratio increased as the tumor advanced from stage I to stage IV (Table 3).

326 Relationship between the BRAFV600E allele ratio and tumor recurrence

327 risk

328 We analyzed the postoperative clinicopathological characteristics of all 329 PTC patients according to the 2015 ATA guidelines for the risk stratification 330 standard of thyroid cancer recurrence. As a result, 169 patients were 331 considered low risk, 140 were considered intermediate risk, and 20 were 332 considered high risk. The median ratios of the BRAFV600E alleles were 7.33%, 333 12.87% and 16.55% for low-, intermediate- and high-risk patients, respectively, 334 with a significant difference (p < 0.001). Moreover, the ratio of the BRAFV600E 335 alleles increased as the risk of tumor recurrence increased (Table 3).

336

337 **DISCUSSION**

Although the BRAFV600E mutation has been linked to the occurrence and 338 339 development of PTC and associated with its clinicopathological characteristics 340 since 2003, the results are still debatable. Several factors contribute to the 341 inconsistent data. First, the different detection methods used can result in wide 342 variations in the rate of BRAF mutations found in PTC. For example, the positive rate of BRAFV600E detected by NGS in PTC is usually over 80%(33), 343 344 whereas that detected by Sanger sequencing is approximately 45-59%(34). 345 Currently, most studies use a qualitative analysis rather than a quantitative 346 analysis of BRAFV600E mutations. Second, the difference in the number of 347 cases analyzed may lead to various outcomes. Gandolfi et al studied 132 cases 348 of PTC and concluded that the occurrence and percentage of the BRAFV600E 349 mutated allele did not have an obvious role in the development of PTC 350 metastases and that the average mutated allele percentage decreased as PTC 351 progressed from the primary location to sites of lymph node metastasis(35). Thus, their results suggest that the less frequent the BRAFV600E mutation is, 352 353 the more aggressive the tumor, which opposes the common concept of the pathologic function of BRAFV600E in PTC(36,37). It is generally believed that 354 355 results from a small number of cases are not reliable. Third, the difference may

356 be caused by the analysis of different clinicopathological indexes. Previous 357 studies included the tall cell and follicular subtypes with traditional PTC and 358 found that BRAFV600E mutations were exactly related to tumor 359 aggressiveness. However, if nontraditional PTC was excluded, no correlation 360 was found(34,38,39). Therefore, unified, traditional PTC must be included to assess its correlation with BRAFV600E mutations. Finally, different disease 361 stages may also contribute to the variation. For example, Gan et al. reported 362 363 that BRAFV600E was closely associated with the clinicopathological 364 characteristics of patients with stage II or above PTC, but such an association 365 was not observed in patients with stage I PTC(40). Therefore, the difference in 366 the proportion of PTC patients in different tumor stages may also contribute to 367 the variation. In this study, we employed the most updated detection 368 technology to quantitatively analyze BRAFV600E mutations in 329 patients 369 with traditional PTC. To the best of our knowledge, this is the largest number of 370 PTC cases studied so far. We selected a total of 11 clinicopathological 371 characteristics for the analysis, the most comprehensive and greatest number 372 of indexes analyzed thus far.

This study found that the sensitivity of ddPCR to detect BRAFV600E mutations in PTC was almost equal to that of NGS, and higher than that of ARMS (Table1). The BRAFV600E mutation was undetectable by ARMS but detectable by ddPCR in 13 patients. Among the 329 PTC patients, the ratio of 19

BRAFV600E alleles in 165 cases was less than 10%, which is usually beyond the range detected by the first-generation gene detection technology(26,41).

379 The aggressiveness of PTC is usually determined by tumor size, capsule 380 and extrathyroidal invasion, LNM, and pulmonary and bone metastasis. These clinicopathological features of PTC can directly indicate the tumor stage and 381 382 objectively reflect the risk of tumor recurrence. These indexes have been 383 consistently recognized and used to guide the clinical diagnosis and treatment 384 of PTC. In our study, the BRAFV600E allele ratio but not the BRAFV600E 385 mutation in PTC tissues was positively correlated with these features. Therefore, the aggressiveness of PTC can be reliably assessed by the 386 387 quantitative index of the BRAF600E allele ratio, making the BRAFV600E allele 388 ratio a molecular marker for the clinical evaluation of PTC aggressiveness.

389 The detection of the BRAFV600E allele ratio can be influenced by the 390 coexistence of other pathologic conditions in the thyroid. The study by Colombo 391 et al indicated that some wild-type BRAF alleles detected in PTC were in fact 392 from inflammatory or stromal cells, regarded as "contamination" (42). 393 Accordingly, the frequency of mutated alleles must be normalized to the 394 percentage of neoplastic cells in the samples(43). After the exclusion of 395 contamination, we found significant differences in the BRAFV600E mutation 396 ratio in the whole group of PTC, which presented different biological behaviors

397 and clinical characteristics.

398 It is well known that a proportion of PTC can coexist with or develop from 399 HT, an autoimmune disease. In this study, we stratified PTC patients with or without HT and found that PTC patients with HT had a lower BRAFV600E allele 400 401 ratio than those without. Moreover, the proportion of stage I PTC patients with 402 HT was significantly higher than that of those without (Table 4). These 403 observations are supported by the fact that the lymphocytic infiltration of HT is a 404 protective factor against PTC progression(44). This clinical phenomenon can 405 also be explained by another finding in our study: PTC patients with HT carried fewer BRAFV600E mutations are likely to be less aggressive. However, the 406 407 mechanism responsible is unclear. It is possible that inflammation in the thyroid 408 may prevent the occurrence of BRAFV600E mutations or have a negative 409 impact on BRAFV600E mutations.

The risk stratification of PTC recurrence recommended by the ATA in 2015 has important clinical guiding value for postoperative iodine-131 treatment and follow-up(27). In our study, the median ratio of BRAFV600E alleles in low-, intermediate- and high-risk patients was 7.33%, 12.87%, 16.55%, respectively, with a significant difference (p<0.001). It was noted that the size of the tumor may not always be positively correlated with the ratio of BRAFV600E alleles. For example, in the high-risk group, the tumor diameter of some patients was

417	only 6 mm, but the BRAFV600E allele ratio was up to 14.3%. However, in the
418	low-risk group, the tumor diameter of some patients reached 12 mm, while the
419	BRAFV600E allele ratio was only 0.2%. Therefore, it is more accurate or
420	meaningful to evaluate the risk of recurrence of PTC by quantitatively detecting
421	the BRAF allele ratio rather than measuring the tumor diameter. Furthermore, if
422	quantitative detection of the BRAF allele ratio is applied in a sample obtained
423	from preoperative FNA, this concept and technique will provide important
424	guidance for decisions regarding the management of PTC, including the pattern
425	of thyroidectomy and cervical lymph node dissection.

Several limitations to this study should be acknowledged. First, in this study, 426 427 83.58% of PTC patients had the BRAFV600E mutation, and 16.42% did not, 428 indicating that the BRAFV600E mutation is not the only factor contributing to 429 the occurrence and development of PTC. Though the BRAFV600E mutation is the most frequent genetic event found in PTC, other genetic changes such as 430 TERT, KRAS and HRAS mutations, RET fusions, and TRK rearrangements 431 432 have also been reported(42,45). Therefore, an accurate risk stratification of 433 PTC requires not only a mutation analysis of a single genetic event, but also a 434 comprehensive analysis of other types of genetic alterations. Second, parts of 435 the tumor tissues subjected to genetic testing and staining may not be matched 436 exactly. Third, since intratumor heterogeneity is objective, tumor tissues 437 subjected to mutation detection may not be representative of the whole 22

438	tumor(46). To the best of our knowledge, the sample number we examined was
439	the largest so far, but selection bias, which affects the detection results, cannot
440	be excluded. Finally, our work is a single-center retrospective study, and a
441	multicenter prospective study is required to further evaluate the prognostic
442	significance of the ratio of BRAFV600E alleles in PTC.

443

444 **CONCLUSIONS**

ddPCR can accurately and quantitatively detect the BRAFV600E allele
ratio in PTC. The BRAFV600E allele ratio is closely related to the clinical
aggressiveness of PTC and can reflect the biological behavior of PTC.
Therefore, it can be used as a molecular-based stratification index of
recurrence risk and should aid in decisions regarding the clinical diagnosis and
treatment of PTC.

451

452 **ACKNOWLEDGMENTS**

This work was supported by grant from the Key Project of Scientific and Technological Innovation in Hangzhou (award number: 20131813A08) and the Medical Science Research Program of Hangzhou (award number: OO20190490). The authors are grateful to all members of the Department of

- 457 Surgical Oncology, Centre of Translational Medicine, and Department of
- 458 Pathology at Hangzhou First People's Hospital.

459 AUTHORS CONTRIBUTIONS

- 460 DC.L and YQ.N designed the study and wrote the paper. YP.X, P.Z, JJ.S and
- 461 S.L analyzed the data and performed the study. F.W, TH.Z, SH.S and KN.L
- 462 contributed with data collection and patients follow-up. DC.L and SR.Z
- supervised the whole process and critically revised the paper. All authors read
- and approved the final version.

465 **AUTHOR DISCLOSURE STATEMENT**

- 466 The authors declare that there are no conflicts of interest.
- 467

468 **REFERENCES**

475

- 469 1. Siegel RL, Miller KD, Jemal A 2019 Cancer statistics, 2019. CA: a
 470 cancer journal for clinicians 69:7-34.
- 471 2. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA,
 472 Smit JW 2006 Survival and death causes in differentiated thyroid
 473 carcinoma. J Clin Endocrinol Metab 91:313-319.
- 474 **3.** Jarząb B, Dedecjus M, Handkiewicz-Junak D, Lange D, Lewiński A,

Nasierowska-Guttmejer A, Ruchała M, Słowińska-Klencka D, Nauman J,

- 476 Adamczewski Z, Bagłaj M, Bałdys-Waligórska A, Barczyński M,
 477 Bednarczuk T, Cichocki A, Czarniecka A, Czepczyński R, Gawlik A,
- Hubalewska-Dydejczyk Α. Jażdzewski K. Kamiński G. 478 Karbownik-Lewińska M, Kos-Kudła B, Kułakowski A, Kuzdak K, Łącka 479 480 K, Małecka-Tendera E, Niedziela M, Pomorski L, Sporny S, Stojcev Z, 481 Syrenicz A, Włoch J, Krajewska J, Szpak-Ulczok S, Kalemba M, Buziak-Bereza M 2016 Diagnostics and Treatment of Thyroid 482 Carcinoma. Endokrynol Pol 67:74-107. 483
- Jarząb B, Dedecjus M, Słowińska-Klencka D, Lewiński A, Adamczewski
 Z, Anielski R, Bagłaj M, Bałdys-Waligórska A, Barczyński M,
 Bednarczuk T, Bossowski A, Buziak-Bereza M, Chmielik E, Cichocki A,
 Czarniecka A, Czepczyński R, Dzięcioł J, Gawlik T, Handkiewicz-Junak

488		D, Hasse-Lazar K, Hubalewska-Dydejczyk A, Jażdżewski K,
489		Jurecka-Lubieniecka B, Kalemba M, Kamiński G, Karbownik-Lewińska
490		M, Klencki M, Kos-Kudła B, Kotecka-Blicharz A, Kowalska A, Krajewska
491		J, Kropińska A, Kukulska A, Kulik E, Kułakowski A, Kuzdak K, Lange D,
492		Ledwon A, Lewandowska-Jabłońska E, Łącka K, Michalik B,
493		Nasierowska-Guttmejer A, Nauman J, Niedziela M, Małecka-Tendera E,
494		Oczko-Wojciechowska M, Olczyk T, Paliczka-Cieślik E, Pomorski L,
495		Puch Z, Roskosz J, Ruchała M, Rusinek D, Sporny S, Stanek-Widera A,
496		Stojcev Z, Syguła A, Syrenicz A, Szpak-Ulczok S, Tomkalski T, Wygoda
497		Z, Włoch J, Zembala-Nożyńska E 2018 Guidelines of Polish National
498		Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018
499		Update. Endokrynol Pol 69:34-74.
500	5.	Xing M 2013 BRAF V600E mutation and papillary thyroid cancer. JAMA
501		310 :535.
502	6.	Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK,
503		Youn YK, Kim KH, Cho BY, Park DJ 2012 The association of the
504		BRAF(V600E) mutation with prognostic factors and poor clinical
505		outcome in papillary thyroid cancer: a meta-analysis. Cancer
506		118 :1764-1773.

507 7. Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAF V600E mutation

508

and its association with clinicopathological features of papillary thyroid

509		cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570.
510	8.	Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF
511		mutation in papillary thyroid cancer and its value in tailoring initial
512		treatment: a systematic review and meta-analysis. Medicine (Baltimore)
513		91 :274-286.
514	9.	Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role,
515		molecular bases, and clinical implications. Endocr Rev 28:742-762.
516	10.	Lin K, Wang O, Zhang X, Dai X, Hu X, Qu J 2010 The BRAF mutation is
517		predictive of aggressive clinicopathological characteristics in papillary
518		thyroid microcarcinoma. Ann Surg Oncol 17 :3294-3300.
519	11.	Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M,
520		Marais R, Pritchard C 2005 Expression of endogenous oncogenic
521		V600EB-raf induces proliferation and developmental defects in mice
522		and transformation of primary fibroblasts. Cancer Res 65:11493-11500.
523	12.	Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM,
524		Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R 2004
525		Mechanism of activation of the RAF-ERK signaling pathway by
526		oncogenic mutations of B-RAF. Cell 116 :855-867.

527	13.	Sithanandam G, Kolch W, Duh FM, Rapp UR 1990 Complete coding
528		sequence of a human B-raf cDNA and detection of B-raf protein kinase
529		with isozyme specific antibodies. Oncogene 5 :1775-1780.

- 530 14. Arcila M, Lau C, Nafa K, Ladanyi M 2011 Detection of KRAS and BRAF
- 531 mutations in colorectal carcinoma roles for high-sensitivity locked 532 nucleic acid-PCR sequencing and broad-spectrum mass spectrometry 533 genotyping. J Mol Diagn **13**:64-73.
- Lamy PJ, Castan F, Lozano N, Montélion C, Audran P, Bibeau F,
 Roques S, Montels F, Laberenne AC 2015 Next-Generation Genotyping
 by Digital PCR to Detect and Quantify the BRAF V600E Mutation in
 Melanoma Biopsies. J Mol Diagn 17:366-373.
- 538 16. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J 2003 NRAS and
 539 BRAF mutations arise early during melanoma pathogenesis and are
 540 preserved throughout tumor progression. Clin Cancer Res
 541 9:6483-6488.
- Li X, Li E, Du J, Wang J, Zheng B 2019 BRAF mutation analysis by
 ARMS-PCR refines thyroid nodule management. Clin Endocrinol (Oxf)
 91:834-841.
- Ren H, Shen Y, Hu D, He W, Zhou J, Cao Y, Mao Y, Dou Y, Xiong W,
 Xiao Q, Zhang Y, Su X 2018 Co-existence of BRAF(V600E) and TERT

547	promoter mutations in papillary thyroid carcinoma is associated with
548	tumor aggressiveness, but not with lymph node metastasis. Cancer
549	Manag Res 10 :1005-1013.

- 550 19. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY,
- Clayman GL 2015 Association of TERT Promoter Mutation, But Not
 BRAF Mutation, With Increased Mortality in PTC. J Clin Endocrinol
 Metab **100**: E1550-E1559.
- Zheng X, Peng C, Gao M, Zhi J, Hou X, Zhao J, Wei X, Chi J, Li D, Qian
 B 2019 Risk factors for cervical lymph node metastasis in papillary
 thyroid microcarcinoma: a study of 1,587 patients. Cancer Biol Med
 16:121-130.
- Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I,
 Moccia T, Budillon A, Vitale M 2012 A high percentage of BRAFV600E
 alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin
 Endocrinol Metab **97**:2333-2340.
- Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I,
 Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary
 occurrence of BRAFV600E is a rare clonal event in papillary thyroid
 carcinoma. J Clin Endocrinol Metab **97**:517-524.
- Reid AL, Freeman JB, Millward M, Ziman M, Gray ES 2015 Detection of
 29

- 567 BRAF-V600E and V600K in melanoma circulating tumour cells by 568 droplet digital PCR. Clin Biochem **48**:999-1002.
- 569 24. Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R,

570 Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A

- 5712015 Quantitative cell-free circulating BRAFV600E mutation analysis by572use of droplet digital PCR in the follow-up of patients with melanoma
- being treated with BRAF inhibitors. Clin Chem **61**:297-304.
- Sho S, Court CM, Kim S, Braxton DR, Hou S, Muthusamy VR, Watson
 RR, Sedarat A, Tseng H-R, Tomlinson JS 2017 Digital PCR Improves
 Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy
 Specimens. PLoS ONE 12:e0170897.
- Ylli D, Patel A, Jensen K, Li ZZ, Mendonca-Torres MC, Costello J,
 Gomes-Lima CJ, Wartofsky L, Burman KD, Vasko VV 2019 Microfluidic
 Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT
- 581 Mutations in Papillary Thyroid Carcinomas. Cancers (Basel) **11**:1916.
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ,
 Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M,
 Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L
 2016 2015 American Thyroid Association Management Guidelines for
 Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:

587	The American Thyroid Association Guidelines Task Force on Thyroid
588	Nodules and Differentiated Thyroid Cancer. Thyroid 26:1-133.

589 28. Amin E, Greene F, Byrd D, Brookland R, Washington M 2017 AJCC

590 Cancer Staging Manual. 8th ed. New York: Springer International.

- Endocrinology Branch Of Chinese Medical Association 2008 [Chinese
 thyroid disease diagnosis and treatment guidelines-thyroiditis: subacute
 thyroiditis]. Chinese journal of internal medicine 47:784-785.
- 594**30.**Guan H, de Morais NS, Stuart J, Ahmadi S, Marqusee E, Kim MI,595Alexander EK 2019 Discordance of serological and sonographic

markers for Hashimoto's thyroiditis with gold standard histopathology.

597 Eur J Endocrinol **181**:539-544.

- 598 31. Zheng G, Lin MT, Lokhandwala PM, Beierl K, Netto GJ, Gocke CD,
- Eshleman JR, McCarthy E, Illei PB 2016 Clinical mutational profiling of
 bone metastases of lung and colon carcinoma and malignant
 melanoma using next-generation sequencing. Cancer Cytopathol
 124:744-753.
- 32. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES,
 Getz G, Mesirov JP 2011 Integrative genomics viewer. Nat Biotechnol
 29:24-26.

606	33.	Yu FX, Hu MX, Zhao HX, Niu LJ, Rong XY, Li WH, Zhu Q, Ying JM, Lyu						
607		N 2019 Precise Detection of Gene Mutations in Fine-Needle Aspiration						
608		Specimens of the Papillary Thyroid Microcarcinoma Using						
609		Next-Generation Sequencing. Int J Endocrinol 2019:4723958.						
610	34.	Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ,						
611		Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P,						
612		Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD,						
613		Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a						
614		poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol						

- 615 Metab **90**:6373-6379.
- Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S,
 Ciarrocchi A 2013 Allele Percentage of theBRAFV600E Mutation in
 Papillary Thyroid Carcinomas and Corresponding Lymph Node
 Metastases: No Evidence for a Role in Tumor Progression. J Clin
 Endocrinol Metab 98:E934-E942.
- 36. Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR, Park GS, Jung CK 2014
 Quantification of BRAF V600E alleles predicts papillary thyroid cancer
 progression. Endocr Relat Cancer 21:891-902.
- 624 **37.** Liu L, Chang JW, Jung SN, Park HS, Oh T, Lim YC, Koo BS 2016
 625 Clinical implications of the extent of BRAFV600E alleles in patients with

626 papillary thyroid carcinoma. Oral Oncol 62:72-77.

627	38.	Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA						
628		2013 Lack of association of BRAF mutation with negative prognostic						
629		indicators in papillary thyroid carcinoma: the University of California,						
630		San Francisco, experience. JAMA Otolaryngol Head Neck Surg						
631		139 :1164-1170.						

- 632 39. Ma H, Wang R, Fang J, Zhong Q, Chen X, Hou L, Feng L, Chen X, 633 Huang Z, Zhao H 2020 A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis 634 in papillary thyroid cancer. Medicine (Baltimore) 99:e18917.
- 40. Gan X, Shen F, Deng X, Feng J, Lu J, Cai W, Peng L, Zheng W, Wang 636

635

- W, Huang P, Chen Z, Guo M, Xu B 2020 Prognostic implications of the 637 638 BRAF-V600(E) mutation in papillary thyroid carcinoma based on a new cut-off age stratification. Oncol Lett 19:631-640. 639
- Pesenti C, Muzza M, Colombo C, Proverbio MC, Farè C, Ferrero S, 640 41. Miozzo M, Fugazzola L, Tabano S 2018 MassARRAY-based 641 simultaneous detection of hotspot somatic mutations and recurrent 642 fusion genes in papillary thyroid carcinoma: the PTC-MA assay. 643 Endocrine 61:36-41. 644

42. Colombo C, Muzza M, Proverbio MC, Tosi D, Soranna D, Pesenti C, 645 33

646		Rossi S, Cirello V, De Leo S, Fusco N, Miozzo M, Bulfamante G,
647		Vicentini L, Ferrero S, Zambon A, Tabano S, Fugazzola L 2019 Impact
648		of Mutation Density and Heterogeneity on Papillary Thyroid Cancer
649		Clinical Features and Remission Probability. Thyroid 29 :237-251.
650	43.	Finkel A, Liba L, Simon E, Bick T, Prinz E, Sabo E, Ben-Izhak O,
651		Hershkovitz D 2016 Subclonality for BRAF mutation in papillary thyroid
652		carcinoma Is associated with earlier disease stage. J Clin Endocrinol
653		Metab 101 :1407-1413.
654	44.	Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, Faggiano A,
655		Colao A, Vitale M 2013 BRAF mutation positive papillary thyroid
656		carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic
657		infiltration is present. Clin Endocrinol (Oxf) 79 :733-738.
658	45.	Lu Z, Zhang Y, Feng D, Sheng J, Yang W, Liu B 2017 Targeted next
659		generation sequencing identifies somatic mutations and gene fusions in
660		papillary thyroid carcinoma. Oncotarget 8:45784-45792.
661	46.	Fugazzola L, Muzza M, Pogliaghi G, Vitale M 2020 Intratumoral genetic
662		heterogeneity in papillary thyroid cancer: occurrence and clinical
663		significance. Cancers (Basel) 12 : 383.

Table 1. The positive rate of BRAFV600E mutation detected by ddPCR

and ARMS in PTC

	BRAF-positive	BRAF-negative	χ ²	P value
ddPCR	274(83.28%)	55(16.72%)	1.225	0.268
ARMS	263(79.94%)	66(20.06%)		

36

Table 2. The relationship between BRAFV600E mutation status and

clinicopathological features in PTC patients

Clinicopathological	Number,	BRAF-negative,	BRAF-positive,	χ ² /Ζ	P value
features	n(%)	n(%)	n(%)		
	329	54	275		
Gender				0.133	0.715
Female	237(72.0%)	40(74.1%)	197(71.6%)		
Male	92(28.0%)	14(25.9%)	78(28.4%)		
Age, years		49(35-55)	48(36-57)	-0.267	0.790
(median and					
interquartile)					
<55	227(69.0%)	40(74.1%)	187(68.0%)	0.778	0.378
≥55	102(31.0%)	14(25.9%)	88(32.0%)		
Multifocality				0.583	0.445
Unifocal	223(67.8%)	39(72.2%)	184(66.9%)		
Multifocal	106(32.2%)	15(27.8%)	91(33.1%)		
Tumor size		7(5-11)	8(6-12)	-1.360	0.174

(median	and					
interquartile)						
≤10		231(70.2%)	40(74.1%)	191(69.5%)	0.677	0.768
11-20		75(22.8%)	10(18.5%)	65(23.6%)		
>20		23(7.0%)	4(7.4%)	19(6.9%)		
Capsule/extrath	nyro				1.027	0.311
idal invasion						
Non-invasion		218(66.3%)	39(72.2%)	179(65.1%)		
Invasion		111(33.7%)	15(27.8%)	96(34.9%)		
Hashimoto's					6.789	0.009
thyroiditis						
Non-combined		242(73.6%)	32(59.3%)	210(76.4%)		
combined		87(26.4%)	22(40.7%)	65(23.6%)		
Status of LNM [#]					3.615	0.169
Non-metastasis	6	175(53.2%)	35(64.8%)	140(50.9%)		
Low-volume		71(21.6%)	8(14.8%)	63(22.9%)		
metastasis						

38

High-volume	83(25.2%)	11(20.4%)	72(26.2%)		
metastasis					
TNM stage					
I	282(85.7%)	52(96.3%)	230(83.6%)	5.617	0.052
II	40(12.2%)	2(3.7%)	38(13.8%)		
III+IV	7(2.1%)	0(0.0%)	7(2.5%)		
Risk stratification				3.543	0.161
of recurrence					
Low	169(51.4%)	34(63.0%)	135(49.1%)		
Inter	140(42.6%)	17(31.5%)	123(44.7%)		
High	20(6.0%)	3(5.6%)	17(6.2%)		

[#]The definition of status of lymph node metastasis:

1. Low-volume metastasis: ≤5 pathologic metastatic lymph nodes (foci <2mm in largest dimension measured under the microscopy).

 High-volume metastasis: (1) >5 pathologic metastatic lymph nodes; (2) metastatic lymph nodes foci ≥2 mm in largest dimension measured under the microscopy.

39

Table 3 . The relationship between the ratio of BRAFV600E alleles and

clinicopathological features in PTC patients The ratio of BRAFV600E alleles(%), Clinicopathological features Z/Z^* P value median(interguartile range) Gender -0.830 0.407 Female 9.40(2.23-20.31) Male 11.95(2.70-22.29) Age, years -1.239 0.215 <55 8.80(1.74-21.13) ≥55 12.19(4.55-19.70) Multifocality -0.326 0.745 Unifocal 9.40(2.13-20.38) Multifocal 10.48(2.59-20.36) Tumor diameters, mm 27.574* < 0.001 ≤10 8.13(1.66-15.20)

11-20	20.29(5.38-26.25)		
>20	32.67(2.13-40.56)		
Capsule/extrathyroidal		-3.735	<0.001
invasion			
Non-invasion	7.64(1.61-17.47)		
Invasion	15.20(6.21-26.25)		
Hashimoto's thyroiditis		-5.236	<0.001
Non-combined	12.64(4.67-23.82)		
Combined	5.38(0.17-11.11)		
Status of LNM [#]		17.966*	<0.001
Non-metastasis	8.00(1.55-16.22)		
Low-volume metastasis	10.33(2.47-21.14)		
High-volume metastasis	17.17(6.21-30.00)		
TNM stage		10.271*	0.006
I	8.90(1.65-19.92)		

11		14.20(7.49-20.29)		
III+IV		29.00(12.00-38.00)		
Risk	stratification	of	17.342*	<0.001
recurrence	9			
Low		7.33(1.35-15.85)		
Inter		12.87(5.06-25.77)		
High		16.55(1.13-29.64)		

Note: **Z/Z*:** Mann-Whitney U test /Kruskal-Wallis H test were used for

continuous abnormally distributed variables.

[#]The definition of status of lymph node metastasis:

1. Low-volume metastasis: ≤5 pathologic metastatic lymph nodes (foci <2mm

in largest dimension measured under the microscopy).

2. High-volume metastasis: (1) >5 pathologic metastatic lymph nodes;(2)

metastatic lymph nodes foci ≥2mm in largest dimension measured under the microscopy.

42

Table 4. Comparison of BRAFV600E allele ratio and tumor stage between

Hashimoto's thyroiditis and those without in PTC patients

Hashimoto's	s TNM stage, n(%)		χ ²	P value	The ratio of BRAFV600E	P value
thyroiditis	Stage I	Stage II-III-IV			alleles	
Non-combined	201(83.1%)	41(16.9%)	5.274	0.022	12.64(4.67-23.82)	<0.001
Combined	81(93.1%)	6(6.9%)			5.38(0.17-11.11)	



Figure 1. BRAFV600E mutation analysis in tissues sampled by ddPCR and ARMS in 275 PTC patients. The red bars indicate the ratio of BRAFV600E alleles detected by ddPCR (left Y-axis), in which 0.1% used as a cut-off value to define the BRAF-positive. The gray bars indicate the cycle threshold (Ct) detected by ARMS (right Y-axis). The red-thick line and fine line represent BRAFV600E alleles at ratio 1% and 10%, respectively. The gray dotted line indicates Ct value < 35 as a threshold to define the BRAF-positive by ARMS.



Figure 2. Correlation between BRAFV600E alleles ratio and maximal tumor diameter in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and tumor diameter. Lines represent simple linear regression ± 95 % confidence interval. Spearman's rho = 0.413, p<0.0001; simple regression adjusted R² = 0.189, p<0.0001.



Figure 3. Comparison of BRAFV600E alleles ratio between capsule/extrathyroidal invasion and those without in PTC. Note: ***: P value <0.001; The top of columns represents the median, and lines represent ± 95 % confidence interval.





Figure 4. Correlation between BRAFV600E alleles ratio and the number of lymph node metastases in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and the number of LNM. Lines represent simple linear regression \pm 95% confidence interval. Spearman's rho = 0.220, p<0.0001; simple regression adjusted R² = 0.070, p<0.0001.



Figure 5. Correlation between BRAFV600E alleles ratio and the rate of lymph node metastases in PTC. Note: Scatter plot shows the correlation of the ratio of BRAFV600E alleles and the rate of LNM. Lines represent simple linear regression \pm 95% confidence interval. Spearman's rho = 0.232, p<0.0001; simple regression adjusted R² = 0.058, p<0.0001.



Figure 6. Comparison of BRAFV600E alleles ratio between Hashimoto's thyroiditis and those without in PTC. Note: ***: P value <0.001. Vertical scatter plots of the ratio of BRAFV600E alleles grouped by PTC combined Hashimoto's thyroiditis. Lines represent median and interquartile range.



ddPCR ARMS

Cycle threshold (Ct)









	50-		
he ratio of ′ ^{600E} alleles (%)	50	0 0 0 0	
	40-	°888°8	•
	30-		•
	20-		
TI 3RAF ^V	10-		
ш	0-	°8888°880880	
	-	PTC with non-HT	PTC with HT
